Real-World SGLT2 Inhibitor Outcomes in 33 Adult Fontan Circulatory Failure Patients

A real-world, multicenter study of 33 adult patients with Fontan circulatory failure treated with sodium-glucose cotransporter 2 inhibitors (SGLT2i) between January 2017 and October 2024. The dataset, from the ACHIEVE-SGLT2i registry, includes safety, discontinuation, and clinical outcome data, with longitudinal biomarker changes evaluated over one year before and after treatment. It was authored by Ralph M. L. Neijenhuis and last updated in May 2026.

Use Cases

• Assess safety and tolerability of SGLT2 inhibitors based on reported side effects and discontinuation rates.
• Analyze longitudinal changes in serum biomarkers like NT-proBNP before and after treatment initiation.
• Compare clinical outcomes between patients with reduced versus preserved ventricular function (FCFrEF vs. FCFpEF).
• Evaluate real-world efficacy based on FCF-related hospitalization rates pre- and post-treatment.

Strengths

• Includes data from 33 patients with a median follow-up of 8.0 months.
• Provides longitudinal biomarker data (e.g., NT-proBNP) from one year before to one year after treatment.
• Compares outcomes across two distinct patient phenotypes (FCFrEF and FCFpEF).
• Explicitly linked to a registered clinical trial (NCT06932081).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 41.9 KB, indicating limited scope.

Provenance

Source

figshare, from the international ACHIEVE-SGLT2i registry.

Collection Method

Real-world, multicenter registry study.

Time Range

Patient treatment from January 2017 to October 2024, with follow-up data.

Freshness

Last updated 2026-05 08 05:55:52; freshness should be verified.

Geography

Multicenter; specific geography not stated.